CJC-1295 (No DAC) + Ipamorelin (GHRH Analog + Ghrelin Mimetic Blend | Growth Hormone Pathway Research)

Product Info

CJC-1295 No DAC + Ipamorelin is an investigational peptide blend commonly discussed in research settings for its potential relevance to growth-hormone secretagogue pathways, recovery-related models, sleep-associated protocols, and body-composition research. This blend typically combines CJC-1295 without DAC, a short-acting growth hormone–releasing hormone analog, with Ipamorelin, a growth hormone secretagogue often studied for its selective ghrelin-receptor activity.

Unlike metabolic peptides such as tirzepatide or retatrutide, CJC-1295 No DAC + Ipamorelin is not designed around GLP-1, GIP, or glucagon receptor activity. Instead, scientific interest centers on growth hormone pulse signaling, GH/IGF-1 axis research, recovery-related experimental models, sleep-timing protocols, and broader body-composition investigation.

CJC-1295 and Ipamorelin remain investigational in many contexts and should not be marketed as treatments for fat loss, muscle growth, anti-aging, sleep disorders, injury recovery, or hormone deficiency. Both compounds are also listed under the World Anti-Doping Agency's prohibited framework: WADA names CJC-1295 among GHRH analogues and Ipamorelin among growth hormone secretagogues.

Potential research interests observed or discussed

• Growth hormone pulse research
  CJC-1295 No DAC and Ipamorelin are commonly discussed in experimental models involving pulsatile growth hormone release, secretagogue activity, and GH-axis signaling.

• GH/IGF-1 axis investigation
  Because the blend is often studied in relation to growth hormone signaling, research interest frequently extends to IGF-1 response, endocrine feedback, and related pathway analysis.

• Sleep and nighttime protocol interest
  Ipamorelin and CJC-1295 No DAC are often presented in research-oriented protocols involving pre-sleep timing, overnight hormone-pulse modeling, and recovery-associated sleep research.

• Recovery-oriented experimental models
  This blend is frequently discussed in peptide research communities for experimental models involving training recovery, tissue stress response, and restoration-related pathways.

• Body-composition research
  CJC-1295 No DAC + Ipamorelin is often studied in broader investigational contexts related to lean-mass support, fat-loss protocol interest, metabolic signaling, and performance-related research discussions.

• Selective secretagogue interest
  Ipamorelin is often described as a growth hormone secretagogue with research interest around selective ghrelin-receptor activity and GH-release signaling.

• Short-acting protocol interest
  CJC-1295 No DAC is commonly differentiated from DAC-containing versions because it is discussed as a shorter-acting GHRH analog, making it a frequent subject in pulse-oriented research protocols.

• Blend-format research interest
  The 5 mg / 5 mg blend format is commonly discussed because it combines a GHRH analog with a GHS-style peptide, allowing researchers to evaluate combined secretagogue-pathway interest in a single formulation.

Limitations and risks observed or discussed

• Limited human clinical evidence
  Much of the public discussion around CJC-1295 No DAC + Ipamorelin extends beyond the level of controlled human clinical evidence available. More well-designed human trials are needed before safety, dosing, or effectiveness claims can be established.

• Not an FDA-approved medication
  CJC-1295 No DAC + Ipamorelin should not be represented as an FDA-approved treatment for anti-aging, fat loss, muscle growth, sleep, injury recovery, or hormone optimization. Reports on peptide regulation continue to note the distinction between compounded or research-market availability and formal FDA approval.

• Unknown long-term safety profile
  Because controlled long-term human data are limited, the long-term safety profile, interaction risks, appropriate populations, and contraindications are not fully established.

• Hormone-axis concerns
  Because this blend is discussed in relation to GH and IGF-1 signaling, inappropriate use may raise concerns around endocrine disruption, abnormal hormone levels, glucose metabolism, fluid retention, or other hormone-related effects.

• Athlete compliance concerns
  CJC-1295 and Ipamorelin are prohibited in sport under WADA's peptide hormone and growth hormone secretagogue categories, creating significant compliance concerns for tested athletes.

• Claims may exceed the evidence
  Many online claims around "anti-aging," "fat loss," "muscle growth," "sleep improvement," or "recovery enhancement" go beyond what has been proven in controlled human trials.

• Human use requires medical and regulatory caution
  Because this blend remains investigational in many contexts, it should only be handled under appropriate research conditions and should not be used as a substitute for approved medical care.

Website-safe closing line

CJC-1295 No DAC + Ipamorelin 5 mg / 5 mg blend is scientifically interesting for growth hormone secretagogue, recovery-related, sleep-timing, and body-composition research, but human safety and effectiveness remain insufficiently established. This blend is not approved for human clinical use as a treatment and should only be studied under appropriate research conditions. Sterile Labs products are strictly for research use only.